Systems Pharmacology Models Can Be Used to Understand Complex Pharmacokinetic-Pharmacodynamic Behavior: An Example Using 5-Lipoxygenase Inhibitors

Zileuton, a 5‐lipoxygenase (5LO) inhibitor, displays complex pharmaokinetic (PK)‐pharmacodynamic (PD) behavior. Available clinical data indicate a lack of dose–bronchodilatory response during initial treatment, with a dose response developing after ~1–2 weeks. We developed a quantitative systems pharmacology (QSP) model to understand the mechanism behind this phenomenon. The model described the release, maturation, and trafficking of eosinophils into the airways, leukotriene synthesis by the 5LO enzyme, leukotriene signaling and bronchodilation, and the PK of zileuton. The model provided a plausible explanation for the two‐phase bronchodilatory effect of zileuton–the short‐term bronchodilation was due to leukotriene inhibition and the long‐term bronchodilation was due to inflammatory cell infiltration blockade. The model also indicated that the theoretical maximum bronchodilation of both 5LO inhibition and leukotriene receptor blockade is likely similar. QSP modeling provided interesting insights into the effects of leukotriene modulation.

[1]  A. Fajmut,et al.  Role of expression of prostaglandin synthases 1 and 2 and leukotriene C4 synthase in aspirin-intolerant asthma: a theoretical study , 2011, Journal of Pharmacokinetics and Pharmacodynamics.

[2]  E. Chi,et al.  The importance of leukotrienes in airway inflammation in a mouse model of asthma , 1996, The Journal of experimental medicine.

[3]  R. Stein,et al.  Kinetic mechanism of guinea pig neutrophil 5-lipoxygenase. , 1986, The Journal of biological chemistry.

[4]  A. Colosimo,et al.  A kinetic model for lipoxygenases based on experimental data with the lipoxygenase of reticulocytes. , 1987, European journal of biochemistry.

[5]  L. Dubé,et al.  Acute and chronic effects of a 5-lipoxygenase inhibitor in asthma: a 6-month randomized multicenter trial. Zileuton Study Group. , 1996, The Journal of allergy and clinical immunology.

[6]  Neil Benson,et al.  Systems Pharmacology: Bridging Systems Biology and Pharmacokinetics-Pharmacodynamics (PKPD) in Drug Discovery and Development , 2011, Pharmaceutical Research.

[7]  G. Guillemette,et al.  Mechanism of action of leukotriene D4 on guinea pig tracheal smooth muscle cells: roles of Ca++ influx and intracellular Ca++ release. , 1997, The Journal of pharmacology and experimental therapeutics.

[8]  R. Stein,et al.  Kinetic studies on the inactivation of 5-lipoxygenase by 5(S)-hydroperoxyeicosatetraenoic acid. , 1987, Prostaglandins.

[9]  Oleg V. Demin,et al.  Regulation of leukotriene and 5oxoETE synthesis and the effect of 5-lipoxygenase inhibitors: a mathematical modeling approach , 2012, BMC Systems Biology.

[10]  Oleg Demin,et al.  Integration not isolation: arguing the case for quantitative and systems pharmacology in drug discovery and development. , 2011, Drug discovery today.

[11]  R K Jain,et al.  Physiologically based pharmacokinetic model for specific and nonspecific monoclonal antibodies and fragments in normal tissues and human tumor xenografts in nude mice. , 1994, Cancer research.

[12]  M. Merz,et al.  Pharmacokinetics and bioavailability of montelukast sodium (MK‐0476) in healthy young and elderly volunteers , 1997, Biopharmaceutics & drug disposition.

[13]  Reka Albert,et al.  Computational and Experimental Analysis Reveals a Requirement for Eosinophil-Derived IL-13 for the Development of Allergic Airway Responses in C57BL/6 Mice , 2011, The Journal of Immunology.

[14]  S. Rankin,et al.  Mechanisms of Acute Eosinophil Mobilization from the Bone Marrow Stimulated by Interleukin 5: The Role of Specific Adhesion Molecules and Phosphatidylinositol 3-Kinase , 1998, The Journal of experimental medicine.

[15]  R. Dockhorn,et al.  Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: a multicenter, randomized, double-blind trial. Montelukast Clinical Research Study Group. , 1998, Archives of internal medicine.

[16]  T. Reiss,et al.  Analysis of montelukast in mild persistent asthmatic patients with near-normal lung function. , 2001, Respiratory medicine.

[17]  K. Akiyama,et al.  Ligation of Toll-Like Receptor 3 Differentially Regulates M2 and M3 Muscarinic Receptor Expression and Function in Human Airway Smooth Muscle Cells , 2007, International Archives of Allergy and Immunology.

[18]  Ian D Pavord,et al.  Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial , 2012, The Lancet.

[19]  A. Guhlmann,et al.  Metabolism and analysis of cysteinyl leukotrienes in the monkey. , 1986, The Journal of biological chemistry.

[20]  L. Boulet,et al.  Montelukast reduces airway eosinophilic inflammation in asthma: a randomized, controlled trial. , 1999, The European respiratory journal.

[21]  P. Weller,et al.  Eosinophils and cysteinyl leukotrienes. , 2003, Prostaglandins, leukotrienes, and essential fatty acids.

[22]  Y. Kanaoka,et al.  Cysteinyl Leukotrienes and Their Receptors: Cellular Distribution and Function in Immune and Inflammatory Responses1 , 2004, The Journal of Immunology.

[23]  C. Sanderson,et al.  Human interleukin-5 (IL-5) regulates the production of eosinophils in human bone marrow cultures: comparison and interaction with IL-1, IL-3, IL-6, and GMCSF. , 1989, Blood.

[24]  M. Orłowski,et al.  Kinetic studies of sheep kidney gamma-glutamyl transpeptidase. , 1976, The Journal of biological chemistry.

[25]  Luhua Lai,et al.  Dynamic Simulations on the Arachidonic Acid Metabolic Network , 2007, PLoS Comput. Biol..

[26]  R. Hansen,et al.  Pharmacokinetics of Zileuton and Its Metabolites in Patients with Renal Impairment , 1997, Journal of clinical pharmacology.

[27]  W. Busse,et al.  The Effect of Inhibition of 5-Lipoxygenase by Zileuton in Mild-to-Moderate Asthma , 1993, Annals of Internal Medicine.

[28]  K. Chung,et al.  Interleukin-5 induces CD34(+) eosinophil progenitor mobilization and eosinophil CCR3 expression in asthma. , 2001, American journal of respiratory and critical care medicine.

[29]  E. Bleecker,et al.  Anti-inflammatory effects of zileuton in a subpopulation of allergic asthmatics. , 2000, American journal of respiratory and critical care medicine.

[30]  R. Louis,et al.  Plasma histamine and bronchial reactivity in allergic asthma , 1993, Allergy.

[31]  J. Bousquet,et al.  Leukotriene EM4 plasma levels in adult asthmatic patients with variable disease severity , 1997, Allergy.

[32]  L. Dubé,et al.  The Pharmacokinetics of Single Oral Doses of Zileuton 200 to 800mg, its Enantiomers, and its Metabolites, in Normal Healthy Volunteers , 1995, Clinical pharmacokinetics.

[33]  M. Rowland,et al.  Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. , 2006, Journal of pharmaceutical sciences.

[34]  S. Kilfeather,et al.  Leukotriene receptor antagonists and synthesis inhibitors reverse survival in eosinophils of asthmatic individuals. , 2000, American journal of respiratory and critical care medicine.

[35]  P. O'Byrne,et al.  Inhaled leukotriene E(4), but not leukotriene D(4), increased airway inflammatory cells in subjects with atopic asthma. , 2001, American journal of respiratory and critical care medicine.

[36]  R. Panettieri,et al.  Interferon-gamma modulates cysteinyl leukotriene receptor-1 expression and function in human airway myocytes. , 2001, American journal of respiratory and critical care medicine.

[37]  Effect of Treatment with Zileuton, a 5-Lipoxygenase Inhibitor, in Patients with Asthma: A Randomized Controlled Trial , 1997 .

[38]  A. Christopoulos,et al.  Fitting Models to Biological Data Using Linear and Nonlinear Regression: A Practical Guide to Curve Fitting , 2004 .

[39]  R. Mittal,et al.  A Randomized, Comparative, Multicentric Clinical Trial to Assess the Efficacy and Safety of Zileuton Extended-Release Tablets With Montelukast Sodium Tablets in Patients Suffering From Chronic Persistent Asthma , 2013, American journal of therapeutics.

[40]  Sheila Annie Peters,et al.  Early identification of drug-induced impairment of gastric emptying through physiologically based pharmacokinetic (PBPK) simulation of plasma concentration-time profiles in rat , 2008, Journal of Pharmacokinetics and Pharmacodynamics.

[41]  L. J. Woods,et al.  Intracrine Cysteinyl Leukotriene Receptor–mediated Signaling of Eosinophil Vesicular Transport–mediated Interleukin-4 Secretion , 2002, The Journal of experimental medicine.

[42]  K. Amin.  The role of mast cells in allergic inflammation. , 2012, Respiratory medicine.

[43]  Nail M. Gizzatkulov,et al.  DBSolve Optimum: a software package for kinetic modeling which allows dynamic visualization of simulation results , 2010, BMC Systems Biology.

[44]  S. Doglia,et al.  Leukotriene D4-induced activation of smooth-muscle cells from human bronchi is partly Ca2+-independent. , 2001, American journal of respiratory and critical care medicine.

[45]  L. Dubé,et al.  Acute and chronic effects of a 5-lipoxygenase inhibitor in asthma: A 6-month randomized multicenter trial , 1996 .

[46]  T. Haahtela,et al.  Leukotriene E4 and granulocytic infiltration into asthmatic airways , 1993, The Lancet.

[47]  D. Lorrain,et al.  Pharmacodynamics and Pharmacokinetics of AM103, a Novel Inhibitor of 5‐Lipoxygenase‐Activating Protein (FLAP) , 2010, Clinical pharmacology and therapeutics.

[48]  Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma. A randomized controlled trial. Zileuton Clinical Trial Group. , 1996, JAMA.

[49]  A. Guhlmann,et al.  Transport and in vivo elimination of cysteinyl leukotrienes. , 1992, Advances in enzyme regulation.

[50]  B. Haraldsson,et al.  Fluid and protein fluxes across small and large pores in the microvasculature. Application of two-pore equations. , 1987, Acta physiologica Scandinavica.